These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18508287)

  • 1. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.
    Vargas HM; Bass AS; Breidenbach A; Feldman HS; Gintant GA; Harmer AR; Heath B; Hoffmann P; Lagrutta A; Leishman D; McMahon N; Mittelstadt S; Polonchuk L; Pugsley MK; Salata JJ; Valentin JP
    J Pharmacol Toxicol Methods; 2008; 58(2):72-6. PubMed ID: 18508287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model.
    Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ
    J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benchmarking safety pharmacology regulatory packages and best practice.
    Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
    J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.
    Berman CL; Cannon K; Cui Y; Kornbrust DJ; Lagrutta A; Sun SZ; Tepper J; Waldron G; Younis HS
    Nucleic Acid Ther; 2014 Aug; 24(4):291-301. PubMed ID: 24946015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods in safety pharmacology in focus.
    Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
    J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
    Gintant G
    Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
    Lester RM; Olbertz J
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1611-1618. PubMed ID: 27718759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
    Pugsley MK
    J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N; Authier S; Pugsley MK; Curtis MJ
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical cardiovascular safety evaluations of biologics: optimizing the approach and follow-up.
    Hondeghem L; De Clerck F
    BioDrugs; 2012 Oct; 26(5):275-82. PubMed ID: 22909102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.
    Cavero I; Crumb W
    Expert Opin Drug Saf; 2005 May; 4(3):509-30. PubMed ID: 15934857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM; Amouzadeh HR; Engwall MJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation.
    Chiang AY; Mallinckrodt CH; Dmitrienko AA; Leishman DJ
    J Pharmacol Toxicol Methods; 2010; 62(2):143-7. PubMed ID: 20570744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
    Friedrichs GS; Patmore L; Bass A
    J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.